Compare Agilent Technologies Inc (A) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Levi Strauss & Co. — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Levi Strauss & Co. trades at $23.05 (market cap $9.48B). The key difference: Agilent Technologies Inc is far larger — about 3.9× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| A | LEVI | |
|---|---|---|
Market Cap | $37.04B | $9.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $24.83 |
52-Week Low | $110.24 | $17.92 |
Enterprise Value | $38.59B | $10.99B |
Dividend Yield | 0.78% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Levi Strauss (LEVI) trades at $24.66, up 1.02% with bullish technical indicators and strong earnings momentum after three consecutive quarterly beats. The company demonstrates robust profitability with a 61.69% gross margin and 9.52% net margin, supported by a $29.00 analyst consensus price target representing 17.6% upside. Recent news highlights Q2 2026 earnings anticipation and strategic focus on women's apparel expansion.
Outlook remains positive with earnings growth and dividend stability, though risks include inflationary pressures and competitive retail dynamics. The stock's current valuation at 18.15x P/E appears reasonable given 29.19% ROE, but investors should monitor Q2 results on July 8 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
